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Abstract 
Cancer-associated stroma (CAS) profoundly influences progression of tumors including mammary carcinoma (mCA). Canine simple 
mCA represent relevant models of human mCA, notably also with respect to CAS. While transcriptomic changes in CAS of mCA 
are well described, it remains unclear to what extent these translate to the protein level. Therefore, we sought to gain insight into 
the proteomic changes in CAS and compare them with transcriptomic changes in the same tissue. To this end, we analyzed CAS 
and matched normal stroma using laser-capture microdissection (LCM) and LC-MS/MS in a cohort of 14 formalin-fixed paraffin 
embedded (FFPE) canine mCAs that we had previously characterized using LCM-RNAseq. Our results reveal clear differences in 
protein abundance between CAS and normal stroma, which are characterized by changes in the extracellular matrix, the cytoskeleton, 
and cytokines such as TNF. The proteomics- and RNAseq-based analyses of LCM-FFPE show a substantial degree of correlation, 
especially for the most deregulated targets and a comparable activation of pathways. Finally, we validate transcriptomic upregulation 
of LTBP2, IGFBP2, COL6A5, POSTN, FN1, COL4A1, COL12A1, PLOD2, COL4A2, and IGFBP7 in CAS on the protein level 
and demonstrate their adverse prognostic value for human breast cancer. Given the relevance of canine mCA as a model for the human 
disease, our analysis substantiates these targets as disease-promoting stromal components with implications for breast cancer in both 
species. 
Neoplasia (2021) 23, 400–412 















The microenvironment that surrounds cancer cells, the so-called cancer-
associated stroma (CAS), has profound effects on the development and
survival of tumor cells, thereby strongly influencing clinical aspects of the
disease [1–3] . Indeed, CAS has been shown to modulate most of the
hallmarks of cancer in a wide variety of tumors, including breast cancer∗ Corresponding author. 
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m  3] . CAS is composed of a wide array of different non-malignant cells
among them fibroblasts, immune cells, vascular cells, adipocytes, and 
thers) that are embedded into an insoluble extracellular matrix (ECM). 
eprogramming of normal stroma to CAS is strongly driven by the adjacent 
ancer cells. By producing a range of growth factors and proteases which 
odify the surrounding stromal environment (reviewed in [4] ), cancer 
ells remodel the cellular surroundings to their own advantage. To date 
owever, our understanding regarding CAS reprogramming in patient 
amples and the molecular dialogue between CAS and cancer cells remains 
ncomplete. 
Based on clinical, histological and molecular similarities, canine simple 
ammary carcinomas (mCA) are considered an excellent model for human 
reast cancer, also because they overcome several of the limitations of 
enograft or genetically modified rodent tumor models [5–7] . Indeed, canine 
imple mCA not only emulate the biology of human mCA but also feature
any of the genomic aberrations found therein [ 5 , 6 ]. mCA are the most
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frequent tumors in both women and intact female dogs [8] . Canine simple
mCA are malignant epithelial neoplasms that infiltrate the surrounding tissue,
whereby they induce a strong stromal response, and can also give rise to
metastases [9] . Importantly, the similarities between human and canine mCA
are not only limited to the tumor cells, but also extend to reprogramming
of CAS. By analyzing CAS and normal stroma from formalin-fixed paraffin
embedded (FFPE) breast cancer tissue using laser-capture-microdissection
(LCM) through RNA sequencing (RNAseq) and quantitative PCR (RT-
qPCR), we have recently demonstrated the existence of strong molecular
homologies in stromal reprogramming between human and canine mCA
[10–14] . 
While transcriptomic changes in CAS of both human and canine mCA
are beginning to be understood, it remains unclear to what extent these
differences in mRNA abundance actually translate to the protein level.
Thus far, analytic approaches of CAS reprogramming in both human and
canine patient samples of mCA have been mostly focused on analysis of
RNA, therefore reflecting the transcriptional state of the tissue [ 11 , 12 , 15 , 16 ].
However, because RNA levels and protein abundance do not necessarily
correlate [17–19] , it remains entirely unclear to what extent the observed
transcriptional changes translate to the protein level in both human and
canine mCA. To the best of our knowledge, there is only one report describing
proteomic changes during stromal reprogramming in fresh-frozen samples
of human mCA [20] and none for canine mCA. This striking shortage
of data on a highly relevant aspect of tumor biology warrants further
investigation. 
FFPE tissue represents a huge resource of patient material that is
routinely prepared in pathology departments and can be easily stored for
decades. However, FFPE negatively impacts on the quality and quantity of
macromolecules that can be isolated from these tissues, making analysis of
RNA or protein from such tissue challenging. Having already established
RNA analysis of microdissected areas from such tissue, we set out to
define proteomic changes during stromal reprogramming in archival FFPE
patient samples and to compare them with transcriptomic changes in the
same tissue. To this end, we isolated CAS and matched normal stroma
using LCM from a cohort of 14 archival FFPE canine mCAs that we had
previously characterized using LCM-RNAseq [11] , and analyzed them by
LC-MS/MS. 
Material and methods 
Selection of cases for LCM 
CAS and matched normal stroma were isolated from fourteen dog
mammary carcinoma samples that were provided by the Institute of
Veterinary Pathology of the Vetsuisse Faculty Zürich. All samples were
formalin-fixed, paraffin-embedded tissue samples either from the Small
Animal Hospital of Zurich or external cases sent in by veterinarians practicing
in Switzerland. Case selection had been performed as part of an earlier
research project that analyzed the transcriptomic changes in cancer-associated
stroma of 15 cases in detail using RNAseq [11] . The identical samples were
used for this project to be able to compare the proteomic changes with the
results obtained by RNAseq. Original case number 7 had to be excluded as the
paraffin block was not available anymore. Details regarding selection criteria
are described in [13] . Criteria for case selection included female dogs, simple
mammary adenoma, and sufficient tumor stroma content for tissue isolation.
Paraffin blocks were routinely kept at room temperature. Tissue processing
for LCM was performed as described in [10] . All cases were reviewed by a
veterinary pathologist (Alexandra Malbon, Franco Guscetti). Table 1 provides
clinical details, such as age and breed of each patient, sample age and tumor
type, for all cases included in the study. aser-capture microdissection (LCM) 
Laser-capture microdissection was performed using the ArcturusXT Laser 
apture Microdissection System (Thermo Scientific) and the Arcturus 
apSure Macro LCM Caps (Life Technologies). Areas of normal or cancer-
ssociated stroma from the specimen were identified and isolated according
o the manufacturer’s protocol and the criteria described in [ 11 , 13 ]. Isolation
f areas of interest was verified by microscopic examination of the LCM cap
s well as the excised region after microdissection. We collected 2 caps of CAS
nd normal stroma each. After excision, the filled caps containing tissue were
ut on a 1.5 ml centrifuge tube (EppendorfSafe-Lock tubes) and frozen at
20 °C, until further processing. 
ample preparation for proteomic analysis 
For protein extraction, sterile blades and forceps were used to peel off
he two thermoplastic membranes containing the captured cells from the
ap, which were then transferred into a sterile EppendorfSafe-Lock tube.
he excised tissue pieces were rehydrated by adding 900 μl of heptane
nd incubating for 10 min at 30 °C in a thermomixer (800 rpm). After
entrifugation (20 000 × g, 10 min) the heptane was removed, and this
tep was repeated. Subsequently the membranes were washed with 900 μl of
00% ethanol (5 min, RT, 1000 rpm), 200 μl of 90% ethanol (5 min, RT,
000 rpm) and 200 μl of 75% ethanol (5 min, RT, 1000 rpm), and then
tored at −80 °C overnight. Further sample preparation was performed by
sing a commercial iST Kit (PreOmics, Germany) with an updated version
f the protocol. Briefly, the tissues were solubilized in ‘Lyse’ buffer, boiled at
5 °C for 60 minutes and processed with High Intensity Focused Ultrasound
HIFU) for 2 times 60 seconds setting the ultrasonic amplitude to 85%. After
:1 dilution with dH2O, the protein concentration was estimated using the
ubit Protein Assay Kit (Life Technologies, Zurich, Switzerland). Samples 
ere then transferred to the cartridge and digested by adding 50 μl of the
Digest’ solution. After 3 hours of incubation at 37 °C the digestion was
topped with 100 μl of Stop solution. The solutions in the cartridge were
emoved by centrifugation at 3800 × g, while the peptides were retained
y the iST-filter. Finally, the peptides were washed, eluted, dried and re-
olubilized in 20 μL of MS-solution (3% acetonitrile, 0.1% formic acid) for
C-MS-Analysis. 
iquid chromatography-mass spectrometry analysis 
Mass spectrometry analysis was performed on a Q Exactive HF-X
ass spectrometer (Thermo Scientific) equipped with a Digital PicoView 
ource (New Objective) and coupled to a M-Class UPLC (Waters). Solvent
omposition at the two channels was 0.1% formic acid for channel A
nd 0.1% formic acid, 99.9% acetonitrile for channel B. For each sample
 μl of peptides were loaded on a commercial MZ Symmetry C18 Trap
olumn (100 Å, 5 μm, 180 μm × 20 mm, Waters) followed by nanoEase
Z C18 HSS T3 Column (100 Å, 1.8 μm, 75 μm × 250 mm, Waters).
he peptides were eluted at a flow rate of 300 nL/min by a gradient
rom 8 to 27% B in 85 min, 35% B in 5 min and 80% B in 1 min.
amples were acquired in a randomized order. The mass spectrometer was
perated in data-dependent mode (DDA), acquiring a full-scan MS spectra
350 −1400 m/z) at a resolution of 120 000 at 200 m/z after accumulation
o a target value of 3 000 000, followed by HCD (higher-energy collision
issociation) fragmentation on the twenty most intense signals per cycle.
CD spectra were acquired at a resolution of 15 000 using a normalized
ollision energy of 25 and a maximum injection time of 22 ms. The
utomatic gain control (AGC) was set to 100 000 ions. Charge state screening
as enabled. Singly, unassigned, and charge states higher than seven were
ejected. Only precursors with intensity above 250 000 were selected for
S/MS. Precursor masses previously selected for MS/MS measurement were 
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Table 1 
Clinical data from canine patients with simple mammary carcinoma included in this study. 
Case # Gender Breed Age [years] Simple carcinoma Sub type of simple carcinoma 
1 f Basset 12 yes tubular 
2 f Vizsla 10 yes cystic-papillary 
3 f Samoyed 5 yes tubulopapillary 
4 f Maltese 14 yes tubular 
5 f Tibetan Terrier 12 yes tubular 
6 f/n West Highland White Terrier 12 yes tubular-solid 
8 f Chihuahua 8 yes tubulopapillary 
9 f/n Bracke 9 yes cribriform 
10 f/n n.d. 13 yes tubular 
11 f/n Appenzell Mountain Dog 6 yes tubular 
12 f Boxer 9 yes tubulopapillary 
13 f n.d. 4 yes cystic-papillary 
14 f/n Beagle 13 yes tubular 
15 f/n Chihuahua 10 yes tubular 


































































excluded from further selection for 30 s, and the exclusion window was set at
10 ppm. The samples were acquired using internal lock mass calibration on
m/z 371.1012 and 445.1200. The mass spectrometry proteomics data were
handled using the local laboratory information management system (LIMS)
[21] . 
Protein identification and label free protein quantification 
The acquired raw MS data were processed by MaxQuant (version
1.6.2.3), followed by protein identification using the integrated Andromeda
search engine [22] . Spectra were searched against a Uniprot Canis lupus
familiaris reference proteome (taxonomy 9615, canonical version from 2019-
07-29), concatenated to its reversed decoyed fasta database and common
protein contaminants. Carbamidomethylation of cysteine was set as fixed
modification, while methionine oxidation and N-terminal protein acetylation
were set as variable. Enzyme specificity was set to trypsin/P allowing a
minimal peptide length of 7 amino acids and a maximum of two missed
cleavages. MaxQuant Orbitrap default search settings were used. The
maximum false discovery rate (FDR) was set to 0.01 for peptides and 0.05
for proteins. Label free quantification was enabled and a 2 minute window
for match between runs was applied. In the MaxQuant experimental design
template, each file is kept separate in the experimental design to obtain
individual quantitative values. 
Bioinformatics data analysis 
Protein fold changes were computed based on peptide intensity values
reported in the MaxQuant generated peptides.txt file, using linear mixed-
effects models [23] . Pre-processing of the peptide intensities reported in the
peptides.txt file was performed as follows: intensities equal zero were removed,
non-zero intensities were log2 transformed and modified using robust z-score
transformation. Afterwards, for each protein, a mixed-effects model was fitted
to the peptide intensities, and fold changes and p-values were computed
based on this model for each contrast [24] . For a contrast, all the protein
p-values are adjusted using the Benjamini and Hochberg procedure to obtain
the false discovery rate (FDR) [25] . To estimate fold-changes for proteins for
which mixed-effects model could not be fit because of an excess in missing
measurements, the following procedure was applied: First, the mean intensity
for all peptides for each condition was computed. For the proteins with no
measurements, we imputed the peptide intensities using the mean of the
10% smallest average peptide intensities computed in step one. Afterwards,ontrasts (differences between conditions) were computed for each peptide 
nd finally, the median of the peptide estimates was used to provide a per
rotein fold change estimate. 
ata analysis 
All statistical analysis was performed using the ANOVA test. For 
he gene set enrichment analysis and KEGG pathway analysis, the tool 
ebGestalt ( http://www.webgestalt.org) was used. For the comparison of 
he transcriptomic and proteomic data set, the online tool Shiny App ( http:
/fgcz-shiny.uzh.ch/fgcz _ multiOmicsAnalysis _ app/ ) run by the Functional 
enomics Center Zurich, was used. Dog genes (CanFam3.1) were converted 
o human orthologues using Ensembl bioMart (release 100) prior to analysis 
ith MetaCore [72] . For the pathway analysis, the web tool MetaCore from
larivate Analytics was used ( https://portal.genego.com ). 
urvival analysis in human patient cohorts 
Correlation between protein expression and survival of human breast 
ancer patients was assessed using the online tool “KM plotter for breast 
rotein” https://kmplot.com/analysis/ using the standard settings for overall 
urvival (auto select best cutoff). If present in more than one dataset, only data
rom targets that showed the same expression trend in all datasets analyzed 
ere included. 
mmunofluorescence and immunohistochemistry 
FFPE tissue sections (2 μm thickness) were mounted on positively 
harged SuperFrost Plus slides (Thermo Fisher Scientific) and dried overnight 
t 37 °C. Deparaffinization of the slides was performed with four xylene baths
or 5 min each using the Tissue-Tek Prisma and Film (Sysmex), and slides
ere rehydrated using a degressive alcohol series of 100% ethanol, 95% 
thanol, 70% ethanol and distilled water. All immunofluorescence sections 
ere counterstained with 0.1 mg/ml DAPI (Thermo Fisher Scientific) at 
oom temperature for 15 min to visualize nuclei. The anti-CollagenIV-alpha1 
ntibody was from BioRad (2150-1470), and was used at 1:50 dilution at 
 °C overnight after basic antigen retrieval by 20 min incubation in pH 9.0
DTA buffer in a pressure cooker set to 98 °C. The secondary antibody used
as goat anti mouse (Invitrogen A11005, 594), diluted 1:400, and incubated 
or 1 hour at room temperature. The anti-fibronectin antibody was from 
bcam (ab2413), the reaction was run in a Ventana Autostainer using the 
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s  CC2 st. antigen retrieval option, the primary antibody was diluted 1:200
and incubated for 1 h at RT, the reaction was visualized with the RedMap
Kit. 
Graphical display of results 
For visual representation and statistical analysis, the programs GraphPad
Prism ( www.graphpad.com ), Shiny App and MetaCore were used. 
Results 
Proteomic profiling of matched CAS and normal stroma in canine 
simple mammary carcinoma isolated using laser-capture microdissection 
of FFPE samples 
To perform proteomic profiling of CAS reprogramming in canine simple
mCA, we concurrently isolated CAS and matched ‘normal’ stroma (i.e.
stroma that was found adjacent to unaltered mammary glands) using LCM
from 14 clinical FFPE specimens in which we had previously analyzed CAS
reprogramming using RNAseq [11] . Representative images for tissue isolation
and patient characteristics for all cases included in the study can be found in
Table 1 and Supplementary Fig. 1. LC-MS/MS analysis identified 10’858
different peptides corresponding to 2’371 different proteins in the 14 pairs
of normal stroma and CAS that were analyzed ( Fig. 1 A–C, Supplementary
Table 1). When considering only targets for which 2 or more peptides
were detected, 1’591 different proteins could be identified ( Fig. 1 D and
E). Overall, samples of CAS tended to yield a higher number of identified
proteins ( Fig. 1 B, C and E). 
Principal component analysis (PCA) using all identified proteins revealed
a clear separation of CAS from normal stroma, suggesting the difference
between normal stroma and CAS to be among the main sources of variability
in the data ( Fig. 2 A). Differential expression analysis of the proteins with an
adjusted p-value cut-off of 0.05 and a fold-change threshold of 2 revealed
282 proteins to be significantly differentially expressed between CAS and
normal stroma. Of these, 240 were up- and 42 were down-regulated in CAS
compared to normal stroma ( Fig. 2 B, Table 2 , and Supplementary Table 1).
Over-representation analysis of Gene Ontology (GO) terms associated with
biological processes, cellular components, and molecular functions revealed
changes in the following categories: muscle system and contraction, tumor
necrosis factor (TNF) production, organization of the extracellular matrix,
contraction and organization of actin filaments, extracellular space, and
integrin binding ( Fig. 2 C). Overall, these results demonstrate the feasibility
of our approach to identify proteins from microdissected FFPE sections and
reveal clear differences in protein abundance between CAS and normal stroma
from canine mCA. The observed changes are characterized by alterations
in proteins associated with the extracellular matrix, the cytoskeleton, and
cytokines such as TNF. As such, this is the first dataset to assess proteomic
changes between CAS and normal stroma of canine mammary carcinomas. 
Comparison of proteomic and transcriptomic profiling of stromal 
reprogramming reveals comparable results 
To understand how the observed proteomic changes in CAS
reprogramming relate to the underlying transcriptomic changes in the
tissue, we compared the proteomic dataset to RNAseq data that was
previously obtained using the same patient samples and identical approach
to isolate CAS and normal stroma [11] . To compare the two datasets,
we identified the Entrez Gene ID for the proteins for which at least two
peptides had been detected and juxtaposed these to the Gene IDs of the
transcriptomic dataset. 1’377 proteins could be annotated with a Gene ID,
compared to 18’494 targets that were detected using RNAseq. The majorityf the proteomic dataset overlapped with the transcriptomic one, with 1’367
argets that were identified by both approaches ( Fig. 3 A). 10 proteins were not
dentified using transcriptomics, most likely due to annotation deficiencies
etween different databases. RNAseq identified 17’132 transcripts that 
ere not detected at the protein level ( Fig. 3 A). A list of the 10 targets
niquely identified by proteomics can be found in Supplementary Table 2.
omparative studies have found correlations between mRNA and protein 
evels in model organisms to range from relatively weak and uncertain to
oderately positive [ 17 , 18 , 26 ]. In accordance with this, correlation analysis
f the expression changes between CAS and normal stroma for the targets
dentified through both transcriptomics and proteomics for all data points
adjusted p-value threshold 1) revealed a correlation coefficient of R = 0.3626
etween transcriptomics and proteomics ( Fig. 3 B). Restricting the analysis
o the significantly changing targets by setting the threshold of the adjusted
-value to 0.05 increased the correlation coefficient to R = 0.5451 ( Fig. 3 C).
urthermore, linear regression analysis of the top 20 up- and down-regulated
argets from the RNAseq dataset for which the respective proteomic data was
vailable revealed a significant positive correlation with R = 0.7754 ( Fig. 3 D
nd F). A similar picture emerged upon comparison of the top 20 up- and
own-regulated protein targets with their RNAseq counterparts ( Fig. 3 E and
). 
To understand which pathways were enriched in both datasets, 
e performed MetaCore analysis (Clarivate Analytics) of the human 
rthologues obtained using Ensembl bioMart application of all proteomic 
nd transcriptomic targets. The top 10 pathways and the proteins associated
ith them can be found in Fig. 4 A and B. TGF-beta related signaling was
vident in 4/10 pathways (no. 1, 2, 5 and 6), suggesting a strong involvement
f TGF-beta signaling in stromal reprogramming in canine mCA. Pathway
umber 3 identified IL1 beta and endothelin-1 induced fibroblast migration
nd extracellular matrix production, and HIF-1 signaling was found as
umber 4. Furthermore, WNT/beta-catenin signaling was pathway number 
, followed by regulation of epithelial-to-mesenchymal transition (EMT), the 
nvolvement of the IGF family in invasion and metastasis and glucocorticoid-
elated pathways in positions 8, 9 and 10. In summary, these results suggest
hat, while the proteomics-based analysis of LCM-FFPE tissue yields a smaller
et of detected targets, the protein and transcript levels show a substantial
egree of correlation, especially for the most deregulated targets. Moreover,
he results from both approaches reveal a comparable picture with regards to
athway activation during stromal reprogramming in canine mCA. 
roteomic CAS dataset validates deregulation of stromal targets with 
rognostic value for human breast cancer 
CAS can strongly influence both development and progression of 
umors. While canine simple mCA are malignant tumors that can give
ise to metastases, canine simple mammary adenomas are the benign non-
nfiltrative counterpart to these neoplasms. It currently remains unclear 
hether such benign adenomas can progress to become malignant mCA.
o identify genes that potentially influence malignant development of a
umor, we have previously compared transcriptomic changes in CAS from
alignant canine mCAs to adenoma-associated stroma (AAS) from benign 
ammary adenomas [12] . This identified a list of interesting potential
isease-promoting stromal targets that are strongly upregulated in CAS 
rom malignant mCA compared to AAS from benign adenomas, or normal
troma. However, it remains unclear whether these transcriptional changes 
ctually translate to altered protein levels. To understand whether these
otential disease-promoting stromal targets are upregulated at the protein 
evel in CAS, we analyzed the expression of the top 21 targets of this list
Supplementary Table 3) for which proteomic data was obtained. Indeed,
n accordance with the transcriptomic upregulation, all of these 21 targets
ere also significantly upregulated on protein level in CAS versus normal
troma ( Fig. 5 A, Supplementary Table 3). We next aimed to investigate the
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Fig. 1. Overview of number of peptides and proteins identified in CAS and normal stroma from 14 canine mammary carcinomas. A–C) Overview of all 
detected peptides and proteins in the 14 paired samples. A) Summary of findings. B and C) Total number of peptides (B) and proteins (C) identified in 
the individual samples. D and E) Overview of identified proteins for which at least 2 peptides were detected. D) Summary of findings. E) Total number 
of proteins identified in the individual samples. The Y-axis indicates the number of proteins per sample, the X-axis indicates the sample. Normal = normal 



























association of the expression of these 21 proteins with survival. Given the
relevance of CAS from canine mCA for human breast cancer [11] and the
lack of long-term survival data for the canine cases that were included in
this study, we utilized the Kaplan-Meier Plotter (kmplot.com/analysis/) for
breast protein. This online-tool allows to assess the effect of protein levels
in bulk tumor samples on survival in breast cancer patients [27] , based on
previously published datasets [28–30] . For three of these proteins (SFRP2,
SLPI, and SORCS2), there was no expression data available. Strikingly, we
found high expression to be strongly correlated with worse overall survival for
10 out of the remaining 18 proteins (LTBP2, IGFBP2, COL6A5, POSTN,
FN1, COL4A1, COL12A1, PLOD2, COL4A2, and IGFBP7; Fig. 5 B–K)).
Additionally, the five proteins BGN, CDH11, COL15A1, COL8A1, and
COL8A2 showed the same trend, but did not reach the significance threshold
of p = 0.05 (Supplementary Fig. 2). Finally, we validated the increased
expression for Collagen IV by immunofluorescence and for Fibronectin by smmunohistochemistry in CAS compared to normal stroma on the protein 
evel ( Fig. 5 L and M). 
Hence, by validating the deregulation of previously identified 
ifferentially expressed transcripts on protein level, our proteomic analysis 
f CAS reprogramming in canine mCA further substantiates these targets as 
isease-modulating stromal components with implications for breast cancer 
n both humans and dogs. 
iscussion 
CAS is well accepted to play a central role in initiation and progression
f cancer [1–3] . While CAS reprogramming has been analyzed on the 
ranscriptional level, it remains unclear to what extent transcriptomic changes 
herein translate to the protein level, and what the proteomic landscape of 
tromal reprogramming looks like in cancer patient samples. Here, we harness 
Neoplasia Vol. 23, No. xxx 2021 Identification of disease-promoting stromal components by comparative proteomic and transcriptomic profiling of 
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Fig. 2. Proteomic analysis of CAS and normal stroma from canine simple mCA reveals strong stromal reprogramming. A) PCA plot of 14 pairs of CAS and 
normal stroma. PCA was performed using all identified proteins. Normal = normal stroma, tumor = CAS. B) Volcano plot highlighting proteins that are 
differentially expressed between CAS and normal stroma. Red line = adjusted p-value 0.05, X-axis = estimate = log2(FC). Vertical blue dashed lines indicates 
cutoff-fold change of 2. P-values were calculated using the ANOVA test; C) Differently regulated biological processes, cellular components, and molecular 
functions between CAS and normal stroma identified through gene set enrichment analysis. Term = affected gene set; ID = gene ontology accession number; 
normalized enrichment score = log2 (FC) in CAS compared to normal stroma; FDR = false discovery rate, indicating the significance of overlap between gene 























o  the validity of spontaneous canine simple mCA as a relevant model of human
mCA, also with respect to CAS reprogramming, to gain insight into the
proteomic landscape of stromal reprogramming in both human and canine
breast cancer. By analyzing microdissected FFPE tissues using LC-MS/MS,
we present here the first dataset to assess proteomic changes between CAS and
normal stroma of canine mCA. Overall, our results demonstrate the feasibility
to identify proteins from microdissected FFPE sections of patient samples
and reveal clear differences in protein abundance between CAS and normal
stroma in canine mCA. These results will contribute to a better understanding
of the involvement of stromal genes in development and progression of canine
mCA, serve as a basis for further mechanistic studies, and have the potential
to reveal novel prognostic markers as well as therapeutic targets. Archival FFPE patient samples represent a huge resource of patient
aterial that is routinely prepared in pathology departments and can be
asily stored for decades. However, FFPE negatively impacts on the quality
nd quantity of macromolecules that can be isolated from these tissues,
aking analysis of RNA or protein from such tissue challenging. Despite
hese difficulties, recent years have brought a big improvement in extraction
nd analysis methods, rendering the analysis of RNA or proteins from
FPE tissue possible while also demonstrating a good consistency between
esults from FFPE and fresh-frozen tissue [31–33] . Bulk analysis of fresh-
rozen human breast cancer has revealed significant differences between 
alignant and matched non-tumor tissue [34] . The positive aspects in terms
f quality of extracted macromolecules when using fresh-frozen tissue are
406 Identification of disease-promoting stromal components by comparative proteomic and transcriptomic profiling of canine mammary tumors 
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Table 2 
Top 25 up- and down-regulated proteins in CAS compared to normal stroma. 
Uniprot ID Gene Protein name Adjusted P value Log 2 (FC) 
J9NY38 COL8A2 Collagen type VIII alpha 2 chain 1.22E-06 4.91 
E2RS46 FBN2 Fibrillin 2 2.94E-02 4.38 
J9P6G0 COL12A1 Collagen type XII alpha 1 chain 1.14E-288 3.96 
F1Q2Y5 ZG16B Zymogen granule protein 16B - 3.83 
F1PBI6 THBS1 Thrombospondin-1 1.05E-64 3.54 
F1P6H7 FN1 Fibronectin 1.40E-10 3.45 
E2QYZ4 LOXL3 Lysyl oxidase homolog 1.86E-03 3.39 
F1PQD5 COL11A2 Collagen type XI alpha 2 chain - 3.36 
E2RGR7 CCDC80 Coiled-coil domain containing 80 1.52E-02 3.32 
E2R1E3 PAPSS2 3 ′ -phosphoadenosine-5 ′ -phosphosulfate synthase 5.06E-04 3.26 
F1P916 TPM1 Tropomyosin 1 1.66E-02 3.26 
J9P5F1 USO1 General vesicular transport factor p115 6.78E-03 3.19 
F6V544 PDLIM4 PDZ and LIM domain 4 4.91E-05 3.17 
G1K2D8 BGN Biglycan 6.54E-68 3.04 
E2QUL2 VAMP8 Vesicle-associated membrane protein 8 - 2.90 
F1Q2F7 COL6A5 Collagen type VI alpha 5 chain 2.25E-18 2.90 
F1PEN8 BCHE Carboxylic ester hydrolase - 2.89 
E2QSK4 CPXM1 Carboxypeptidase X, M14 family member 1 6.05E-09 2.83 
F1PLN5 FMOD Fibromodulin 1.93E-32 2.71 
F6UTF3 THBS2 Thrombospondin 2 2.69E-09 2.67 
E2R7R1 ISG15 ISG15 ubiquitin like modifier 1.56E-02 2.66 
F6XLB5 PDLIM7 PDZ domain-containing protein 5.49E-08 2.66 
D3YJ60 CHI3L1 Chitinase-3-like protein 1 3.73E-06 2.65 
E2RBA8 PDLIM5 PDZ and LIM domain 5 3.00E-12 2.63 
F1PEQ5 IGFBP5 Insulin-like growth factor-binding protein 5 5.62E-11 2.57 
J9PAT9 HAPLN1 Hyaluronan and proteoglycan link protein 1 1.80E-07 -6.39 
J9NVT5 - 1.79E-03 -6.39 
F1PV96 MYL1 Myosin light chain 1 6.24E-01 -4.56 
F6Y2H4 SERPINE2 Serpin family E member 2 1.05E-03 -3.36 
F1PPC2 LGALS7 Galectin 4.75E-09 -2.77 
E2RHU8 CALML5 Calmodulin-like 5 - -2.43 
J9NYC0 MFAP4 Microfibril-associated protein 4 5.10E-06 -2.33 
E2RPQ6 DPT Uncharacterized protein 1.14E-10 -2.24 
E2RNR0 OGN Mimecan 2.58E-46 -2.20 
F1PGU1 MYLPF Myosin light chain, phosphorylatable, fast skeletal muscle - -2.05 
J9NV52 TNNT1 Troponin T, slow skeletal muscle - -2.01 
Q29393 DCN Decorin 1.74E-48 -1.95 
E2RPS1 V4G C-type lectin domain family 4 member G 3.97E-04 -1.91 
E2R837 UBA2 SUMO-activating enzyme subunit 2 3.61E-02 -1.85 
F1PKX3 F13A1 Coagulation factor XIII A chain 2.56E-15 -1.71 
F1Q3I5 COL1A1 Collagen alpha-1(I) chain 2.31E-45 -1.68 
F1PS24 COL2A1 Collagen type II alpha 1 chain 2.17E-02 -1.67 
J9P0L0 COL3A1 Collagen type III alpha 1 chain 6.46E-09 -1.67 
P15944 N/A Tryptase 1.39E-02 -1.60 
J9NX65 SBSN Uncharacterized protein 5.04E-04 -1.58 
E2R974 FABP4 Adipocyte-type fatty acid-binding protein 2.55E-07 -1.53 
D6BR72 KRT71 Keratin 71 - -1.50 
F1PK58 OLFML1 Olfactomedin like 1 5.80E-08 -1.49 
F1PDZ7 CA2 Carbonic anhydrase 3.91E-02 -1.46 
F1PDJ0 APOC3 Apolipoprotein C-III 3.61E-04 -1.45 
Proteins are ranked by their log2 fold change CAS/normal stroma. Up-regulated proteins have a positive value for log2 ratio, 
down-regulated ones display a negative value for log2 ratio. Proteins without a p-value were exclusively detected in CAS (for the 













a  heavily counterbalanced by the disadvantages that arise through the need
of a high grade of coordination to achieve proper collection and storage.
Furthermore, tissue morphology of fresh-frozen tissue is inferior to that
of FFPE. And finally, using fresh-frozen tissue precludes the use of most
archival samples, which are generally processed as FFPE. Indeed, proteomic
analysis has also been shown to work for microdissected FFPE tissue [ 35 , 36 ].
This possibility to analyze specific areas of archival patient samples byoth RNAseq and proteomics unlocks a novel dimension of hard-to-analyze 
amples for investigation. 
Our approach revealed several interesting insights into CAS- 
eprogramming. Importantly, the most significantly deregulated proteins are 
ll produced by stromal cells, thus validating our approach to isolate and 
nalyze stroma. Some of the proteins, such as Collagen type VIII, Fibrillin 
nd LTBP2, are known to be of mainly stromal origin and are upregulated in
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Fig. 3. Comparison of proteomic and transcriptomic profiling of stromal reprogramming. A) Venn diagram showing the overlap between the proteomic 
(orange) and the transcriptomic (blue) dataset. B) and C) Correlation analysis of the expression changes between CAS and normal stroma for the targets 
identified through both transcriptomics and proteomics for all data points (adjusted p-value threshold 1, B) and for the significantly changing data points 
(adjusted p-value threshold 0.05, C). D and E) Linear regression analysis of the top 20 up- and down-regulated targets from the RNAseq dataset with the 
respective proteomic data (D) and from the proteomic dataset with the respective RNAseq data (E). F and G) Heatmap of top 20 up- and down-regulated 






















m  colorectal cancer [ 37 , 38 ]. Especially the composition of collagens seemed to
shift quite strongly between normal stroma and CAS. The most significantly
upregulated collagens that we found in CAS were the following: COL4A1,
COL6A3, COL8A2, COL11A1, COL11A2, COL12A1, and COL15A1.
Most of the collagens are produced by stromal cells, and fibrillar collagens
and collagen VI for instance are collagens known to be produced by CAFs
(reviewed in [71] ). Collagens have been found to have important roles in
different types of cancer, for example collagen XII in gastric and ovarian
cancer [39–41] , or collagen XI in [42–45] . Additionally, genes of collagen
XI and XII are also among the most upregulated genes in CAS from human
breast cancer [46] . Hence, the up-regulation of these particular collagens on
the protein level is in strong accordance with the findings of other studies. The strong involvement of the tumor necrosis factor (TNF) superfamily,
ith the regulating molecules THBS1, LTF, ACP5, and BPI is in accordance
ith its known role. TNF is frequently upregulated in human epithelial
alignancies such as breast cancer [47–49] . On one hand, TNF affects
umor proliferation and survival, EMT, metastasis and recurrence (reviewed 
n [50] ). On the other hand, TNF possesses some anticancer properties
hrough inducing cancer cell death [51] . Further analysis of the involvement
f the TNF pathway in CAS of canine and human mCA will likely yield
nteresting data. 
Comparative studies have found that correlations between mRNA and 
rotein levels in model organisms can be relatively weak and uncertain or
oderately positive [26] . In our dataset, the correlation coefficient between
408 Identification of disease-promoting stromal components by comparative proteomic and transcriptomic profiling of canine mammary tumors 
using laser-capture microdissected FFPE tissue A. Pöschel et al. Neoplasia Vol. 23, No. xxx 2021 
Fig. 4. Comparable picture of pathway activation between transcriptomic and proteomic data. A) MetaCore pathway analysis of the human orthologues of 




























transcriptomics and proteomics was R = 0.3626, similar to what has been
reported for other tissues before [17–19] . Setting the threshold of the adjusted
p-value at 0.05 increased the correlation coefficient to 0.5451. Similarly,
restricting the analysis to the top 20 targets from either the transcriptomic
or proteomic dataset further increased the correlation, suggesting that the
more strongly targets are deregulated, the more consistent the correspondence
between mRNA and protein levels become. 
The strong role of TGF-beta related signaling that emerged from pathway
analysis is well supported by literature. TGF-beta naturally possesses both
tumor-suppressive as well as tumor-promoting qualities, depending on the
context. As tumor-promoter TGF-beta can support the promotion of tumor
growth and invasion, evasion of immune surveillance, and metastasis [ 52 , 53 ].
Also associated with the TGF-beta pathway is PAI-1 (plasminogen activator
inhibitor-1), a serine protease inhibitor that is strongly upregulated in CAS.AI-1 inhibits tissue plasminogen activator and urokinase, the activators of 
lasminogen and hence fibrinolysis. In cancer, it promotes its invasion and 
etastasis and correlates with poor prognosis in breast cancer [54–56] . In 
ummary, these results suggest that, while the proteomics-based analysis of 
CM-FFPE tissue yields a smaller set of detected targets, the protein and 
ranscript levels show a substantial degree of correlation, especially for the 
ost deregulated targets. Moreover, the results from both approaches reveal 
 comparable picture with regards to pathway activation during stromal 
eprogramming in canine mCA. 
By leveraging the relevance of canine CAS as a model of the human
isease, we establish increased expression of LTBP2, IGFBP2, COL6A5, 
OSTN, FN1, COL4A1, COL12A1, PLOD2, COL4A2, and IGFBP7 to 
e strongly correlated with worse overall survival for human breast cancer 
atients. Validation of increased Collagen IV and Fibronectin on protein 
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Fig. 5. Proteomic CAS dataset validates deregulation of stromal targets with prognostic value for human breast cancer. A) Heatmap of protein expression 
of 21 potential disease-promoting targets as identified by RNAseq. B – K) Kaplan-Meier curves of overall survival for the indicated proteins listed in A) to 
visualize survival differences between high and low-expressing patients (auto select best cutoff) with a follow-up of up to 150 months (dataset Tang_2018) or 
250 months (datasets Liu_2014 and TCGA_RPPA). B) LTBP2, C) IGFBP2, D) COL6A5, E) POSTN, F) FN1, G) COL4A1, H) COL12A1, I) PLOD2, 
J) COL4A2 and K) IGFBP7. L) Immunofluorescent staining of Collagen IV (purple), in CAS and matched normal stroma of a representative canine simple 
mCA sample. Dapi (blue) stains cell nuclei, and marks largely blue areas in the right panels as tumor cells, while demarcating normal mammary glands in the 
panels on the left. Scale bar = 250 μm. M) Immunohistochemistry of fibronectin (pink) in CAS and matched normal stroma of a representative canine simple 
















w  level in canine CAS further substantiates these findings. Of note, PDGFRB
and FAP, two CAS markers that we have previously validated as upregulated
using IHC [13] were also found to be upregulated using proteomics.
LTBP2 is critically involved in regulation of TGF-beta signaling [57] and
its expression is significantly elevated in human breast cancer in correlation
with clinical stage and other adverse prognostic factors [58] . As a regulator
of PI3K signaling, the expression IGFBP2 is strongly correlated with grade
of malignancy in many tumors and especially in breast cancer [59] . CollagenI has been recently identified as driver of invasion and metastasis of breast
ancer and high protein levels of Collagen VI have been found by bulk
umor proteomic analysis of more than 500 human cancers [60–62] . Strongly
levated levels of both POSTN and FN1 are well documented in a wide
ariety of tumors, including breast cancer, and have been shown to promote
umor invasion and metastasis through manifold effects on different cancer
allmarks (reviewed in [ 63 , 64 ]). Similarly, Collagen IV is positively correlated
ith larger and more aggressive breast tumors [65] and has been shown to
410 Identification of disease-promoting stromal components by comparative proteomic and transcriptomic profiling of canine mammary tumors 













































































1  promote cancer cell invasion and migration [66] . High PLOD2 expression
is associated with increased mortality risk in breast cancer [67] . Functionally,
it promotes fibrillar collagen formation and thereby increases tumor stiffness
and is required for metastasis. IGFBP7 expression in tumor cells has been
suggested to be anti-neoplastic [68] . However, when expressed in CAS, it
has growth-promoting effects on tumor cells through a paracrine signaling
mechanism that can promote anchorage-independent growth of tumor cells
[69] . Interestingly, IGFBP7 also binds to Collagen IV [68] . 
The fact that on transcriptomics level only one of the top 10 adverse
genes [12] actually correlates with worse OS, while on the protein level
there are 4 among these top 10 targets that predict worse OS suggests that
proteomic changes could potentially be a better predictor than transcriptomic
changes, at least when it comes to analyzing expression of stromal genes in
bulk tissue. This might be due to the fact that RNAseq data usually turns
back much more differentially expressed targets than proteomics analysis
(in this study we detected 13% of all transcripts on the proteomic level).
Important transcriptomic changes in single targets are therefore more likely
to be ‘overshadowed’ by other targets that might not have anything to do
with OS in contrast to the relatively ‘smaller’ proteomic dataset. Another
possibility is, that proteomic detection could be biased towards the most
abundant proteins, which might also hold more biological relevance. While
it’s currently not possible to finally answer this question, this clearly further
underlines the point that transcriptomic and proteomic changes are not
always in direct concordance and that proteomic profiling of distinct tissue
compartments can provide novel insight into biological questions that go
beyond validation of RNAseq data. 
Collectively, the results presented in this paper will serve as a starting
point for mechanistic follow-up studies to further delineate and strengthen
the role of these stromal genes in development and progression of canine and
human mCA. Hence by validating the deregulation of previously identified
differentially expressed transcripts on protein level, our proteomic analysis
of CAS reprogramming in canine mCA further substantiates these targets as
disease-modulating stromal components with implications for breast cancer
in both humans and dogs. 
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